Sage Therapeutics, Inc. Stock

Equities

SAGE

US78667J1088

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
11.78 USD +4.06% Intraday chart for Sage Therapeutics, Inc. +0.68% -45.64%
Sales 2024 * 42.96M Sales 2025 * 132M Capitalization 709M
Net income 2024 * -397M Net income 2025 * -332M EV / Sales 2024 * 4.79 x
Net cash position 2024 * 503M Net cash position 2025 * 330M EV / Sales 2025 * 2.87 x
P/E ratio 2024 *
-1.81 x
P/E ratio 2025 *
-2.26 x
Employees 487
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.06%
1 week+0.68%
Current month-15.49%
1 month-13.95%
3 months-47.95%
6 months-39.59%
Current year-45.64%
More quotes
1 week
11.10
Extreme 11.1
12.35
1 month
11.00
Extreme 11
14.71
Current year
10.92
Extreme 10.92
28.26
1 year
10.92
Extreme 10.92
59.99
3 years
10.92
Extreme 10.92
79.45
5 years
10.92
Extreme 10.92
193.56
10 years
10.92
Extreme 10.92
195.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-09-30
Founder 73 10-04-15
Director of Finance/CFO 61 13-02-28
Members of the board TitleAgeSince
Director/Board Member 71 13-08-13
Founder 73 10-04-15
Chief Executive Officer 60 20-09-30
More insiders
Date Price Change Volume
24-05-24 11.78 +4.06% 770,833
24-05-23 11.32 -6.45% 1,042,354
24-05-22 12.1 +0.41% 808,951
24-05-21 12.05 +7.78% 2,613,934
24-05-20 11.18 -4.44% 3,913,557

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
11.78 USD
Average target price
22.24 USD
Spread / Average Target
+88.75%
Consensus